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The Aryl hydrocarbon receptor (AhR) ligands exhibiting modulating ac-
tivity represents a new class of anticancer agents that can be directed to-
wards several tumors. We have examined AhR expression in human colon 
cancer and adjacent non-tumor tissue. AhR expression level was about 2-7 
times higher in tumor tissue samples than in the adjacent non-tumor sam-
ples (in 82% of all the samples). We were unable to find any increase of 
ABCG2 expression on the level of the transcription, while the expression 
of MDR2 was increased in half of the tumors compared to the levels of 
expression in normal adjacent tissue. We have used FICZ as a potent high 
affinity ligand of the AhR to calibrate the reporter cell line HEK293T-
AhR-luc as a potent high affinity ligand of the AhR. The concentration of 
xenobiotic response element (XRE) ligands is higher, than in the blood 
of healthy people in 86% of the patients. The proposed test system will 
allow the use of the AhR ligand level as an additional diagnostic marker 
in the treatment of colon cancer.
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1. Introduction
The presence of polycyclic aromatic hydrocar-bons (PAHs) in the environment is a source of concern for specialists in the field of organic 
chemistry, biochemists, environmental chemists and 
geochemists. Many PAHs are potent chemical carcin-
ogens [1]. The deterioration of the environmental situa-
tion is associated with the increase in cancer incidence, 
including colorectal cancer. There were approximately 
1.4 million new cases of colorectal cancer in 2012, 
making it the third and second most common cancer 
globally among men and women, respectively [2].
AhR is an environmental response gene that me-
diates cellular responses to a variety of xenobiotic 
compounds that frequently function as AhR ligands. 
The protein encoded by AhR is a ligand-activated he-
lix-loop-helix transcription factor involved in the reg-
ulation of biological responses to PAHs. The AhR that 
is present in the non-active state is cytosolic. Before 
ligand binding, AhR is sequestered in the cytoplasm; 
upon ligand binding, this protein moves to the nucle-
us and stimulates transcription of target genes after 
binding to specific DNA sequence elements known as 
the xenobiotic response elements (XREs). XREs are 
present in the regulatory region of target genes includ-
ing xenobiotic-metabolizing enzymes (XMEs) such as 
members of cytochrome P450 family (CYP1A1, CY-
P1A2, CYP2B1 and UGT1A6) [3].
Immunostaining of normal intestinal tissue sections 
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allows the localization of AhR in the stroma that con-
tains immune cells and lymphoid follicles, whereas in 
the tumor tissue immunostaining was detected in both 
stromal and tumor cells. Given that, it can be seen that 
AhR expression is increased in tumor tissues. Entero-
cytes of the small intestine have a great ability to de-
toxify PAH, so that the epithelium of the small intestine 
is the first barrier to the absorption of PAH. Barrier 
function is provided by XME and efflux carriers that 
transport metabolites from the cell. ATP-binding cas-
sette subfamily G member 2 (ABCG2) and P-glycopro-
tein (ABCB1/MDR2) is known for mediating the efflux 
of conjugated metabolites of xenobiotics [4-6]. ABCG2 is 
a constitutively expressed ATP-binding cassette (ABC) 
transporter that protects many tissues against xenobiot-
ic molecules.
In various cancers ABCG2 transporters are known 
to produce multidrug resistance (MDR), thereby limit-
ing the clinical response to chemotherapy. They show 
activity that changes the pharmacokinetics of the drugs 
used and diminishes the effectiveness of their delivery 
to tumor cells, causing the formation of multidrug re-
sistance. ABCG2 was also identified as a direct target 
of AhR [7]. AhR abundantly expressed in many different 
types of cancer. Thus, AhR pathway on one hand as-
sists in the eradication of PAHs, but, on the other hand, 
the side effect of its activation is a certain decline of 
treatment efficiency via the chemotherapeutic agent’s 
efflux.
In recent years, the interest of human AHR research 
has shifted to the study of the physiological functions 
of AHR and immunity control [8-10]. Along with its in-
volvement in chemical protection, researchers are most 
interested in its involvement in providing stem cell ho-
meostasis, as well as in modulating the immune system 
[11].
The identification of tumorigenic cancer stem 
cells (CSCs) in colorectal cancer and the mechanism 
contributing to the formation of their qualities and the 
maintenance of homeostasis requires additional study 
and remains unidentified. 
Significantly increasing the effectiveness of spheroid 
formation, resistance to chemotherapy and the ability 
to form tumor xenografts of choriocarcinoma cells after 
activation of AhR by TCDD has been reported recently. 
Expression of ABCG2 is also related to tumorigenic 
CSC in several cancers. The possible role of AhR in 
CSC quality maintenance is highly interesting to the 
application of AhR as a marker of CSC and can be used 
for creating a target drug. 
Based on the studies in recent decades, researchers 
have come to understand the causal role of FCs in sev-
eral human diseases. The role of AhR as a diagnostic 
marker and a possible therapeutic target in the treat-
ment of these pathologies is suggested [12].
There are reporter constructions that allow to esti-
mate the activity of the main signaling pathways under 
the control of the responsive elements to various nucle-
ar receptors by the level of the luciferase expression. 
Although technically not a member of the Nuclear 
Receptor superfamily, the AhR shares many of the 
same attributes. To study the changes in AhR activity 
we have decided to use XRE luciferase reporter. Our 
reporter construct is similar to the plasmid from the 
well-known chemically activated luciferase expression 
(CALUX) system [13] that has been used for the rapid 
and inexpensive detection and relative quantitation of 
dioxin-like chemicals in a wide variety of sample ma-
trices. Although the Caco-2 adenocarcinoma cell line is 
traditionally used as a model to study the intestinal epi-
thelium, we have decided to use HEK293 cells to make 
a xenobiotic responsive cell line. The goal of our study 
was to create a reporter cell line, which will make it 
possible to estimate xenobiotic concentration in a se-
rum of colorectal cancer patients and in tumor tissue. 
HEK293 cell line was used for transfection with the 
reporter construct, which contained the luciferase gene 
under control of a XRE repeated 6 times and a minimal 
promotor. The level of Luc expression, measured in 
the relative units, reflects the concentration of PAHs in 
the culture media of reporter cells line. To calibrate the 
reporter cell line we had used FICZ as a potent high af-
finity ligand of the AhR.
2. Materials and Methods
2.1 Cell Culture
Experiments were done with HEK293T cell line and 
reporter cell line НЕК293Т-AhR-luc. The cells were 
maintained in a DMEM medium (Biolot) with 10% 
bovine embryonic serum (Gibco), penicillin and 
streptomycin (Biolot). The cells that have reached the 
monolayer were subcultured in the ratio of 1:3.
2.2 Tumor and Adjacent Mucosa Samples
Colon adenocarcinoma, adjacent normal tissue and 
blood serum from 11 patients were used in experiments, 
these patients were ranked according to the severity 
and extent of the oncological process, according to the 
clinico-morphological (TNM) classification (Table 1). 
Also blood serum from healthy people was used.
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Table 1. Clinico-pathological characteristics of patients
Note: Main clinico-pathological information of patients. The position in 
the table was determined based on the clinical prognosis coming from 
the pTNM classification and additional prognostic markers (level of 
tumor differentiation, tumor grow rate). F- female, M- male. pTNM - 
Classification system of the anatomical extent of cancer. p - stage given 
by histopathologic examination of surgical sample. T - size of primary 
tumor, N - degree of spread to regional lymph nodes. M – present of dis-
tant metastasis and site.
2.3 RNA Isolation, Synthesis of cDNA and 
qPCR
Total RNA was isolated from cultured cells and tissue 
samples (with preliminary homogenization) using the 
RNeasy Mini Kit (Qiagen). cDNA was generated from 
1 μg of total RNA per sample using the RT M-MuLV–
RH kit (Biolabmix, Russia). qPCR was performed by 
using the CFX96 Touch Real-Time PCR Detection Sys-
tem (Bio-Rad) and the HS-qPCR SYBR Blue kit (Bio-
labmix, Russia). GAPDH and B2M genes were used to 
normalize gene expression. The results are represented 
as a fold induction using the ΔΔCt method.
2.4 Cloning of XRE and Map of the Reporter 
Plasmid 
The plasmid vector pGL4.27(luc2P/minP/Hygro) was 
used for XRE cloning. The vector contains a multiple 
cloning region for insertion of a response element of 
interest upstream of a minimal promoter and the luc2P 
gene. The vector contains an ampicillin resistance gene 
to allow the selection in E. coli and a mammalian se-
lectable marker for hygromycin resistance. KpnI and 
HindIII sites of the polylinker region were used for 
restriction and ligation during the preparation of XRE 
vector under a minimal promoter. The thrice repeated 
21 bp XRE was used as an insert. Synthetic oligonucle-
otides has KpnI and HindIII sites on the ends and after 
annealing were ready for ligation into the restricted 
vector. The oligonucleotides sequences are presented 
below:
F-XRE/KpnI-HindIII (65 bp)
ctg agt tct cac gct agc aga ttg agt tct cac gct agc aga 
ttg agt tct cac gct agc aga ta
R - XRE/HindIII-KpnI (73 bp)
agc tta tct gct agc gtg aga act caa tct gct agc gtg aga 
act caa tct gct agc gtg aga act cag gta c
2.5 Reporter Cell line Creation
After the transfection of a plasmid reporter into 
HEK293T cells with Lipofectamit 2000, clones with 
integrated construct were selected into the culture 
media, containing 100 mkg/ml Hygromycin B. Several 
clones were selected and their response to AhR ligand 
inducible activation of luciferase expression was 
checked out. One clone was chosen and used in the 
presented study as НЕК293Т-AhR-luc cell line.
To calibrate the reporter cell line we have used FICZ 
(Merck) as a potent high affinity ligand of the AhR. 
We used ligand solution in concentration from 100nM 
to 0.032 nM, because this reporter line was created for 
working in the range of nearly physiological concentra-
tion of PAHs. Luciferase assay was performed by using 
the Luciferase Assay Systems (Promega). Cell viability 
was determined with MTT assay after 24 h.
We have determined the expression level of AhR 
and its surrogate target CYP1A in a reporter cell line in 
response to the treatment of FICZ. 7. FORMATTING 
Please, make the figures bigger. Our studies clearly 
show an mRNA increase for CYP1A in response to the 
FICZ (0.8 nM) treatment of the reporter line cells.
2.6 Luc-assay
Increased luciferase activity was used to estimate the 
AhR activation, induced by the components in a culture 
medium. 1.5x104 cells per well were seeded in a 96-
well tissue culture plate in a standard growth medium, 
24 hours prior to the test. On the day of the experiment 
the media was replaced with a fresh growth medium 
containing 10% heat inactivated patient’s blood serum 
or lysate of patient’s tissues. For the preparation of 
colon adenocarcinoma and adjacent normal tissue 
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lysates 25 mg of each samples were taken and placed 
in 500 mkl of buffer solution (20 mM Tris pH 7.6; 
100 mM MaCl; 5 mM MgCl2; 1 mM EDTA). Then 
the samples were disrupted and homogenized with the 
pestle, underwent ultrasound treatment (3 times, 15 
sec each impulse in 80% of maximal intensity) and 
centrifuged for 3 min at maximum speed. The exposure 
within luciferase assay buffer and substrate was 
performed by using the protocol for Luciferase Assay 
Systems (Promega). The cytotoxicity of the compounds 
screened against the НЕК293Т-AhR-luc cell line was 
tested in parallel by measuring the cell viability using 
МТТ-assay. Luminescence intensity of the reaction 
is quantified using a luminometer, and is reported in 
terms of Relative Light Units (RLU’s) per 100 000 
cells. Viability of cells was measured by a colorimetric 
method using MTTassay. Optical density was measured 
at a wavelength of 570 nm against a solution of MTT 
with DMSO on a Multiskan EX spectrophotometer 
(Thermo Electron, USA). The amount of unsoluble 
formazan correlates with the number of viable cells in 
the population. 
2.7 Statistics
RNA level and cell viability were evaluated after three 
identical tests. Statistical difference was calculated in 
the analysis of variance using Statistica 6.0. p<0.05, 
which was considered to be statistically significant. 
Mixed-model analysis of variance (ANOVA) or the 
Student’s t test was used to analyze data from the lucif-
erase reporter assays, and P values less than 0.05 were 
considered as statistically significant.
3. Results
3.1 AhR Expression in Human Colon Cancer
We examined AhR expression in human colon cancer 
and adjacent non-tumor tissue (figure. 1A). RT-PCR 
analysis has revealed that the AhR expression level was 
about 2-7 times higher in tumor tissue samples than in 
adjacent non-tumor samples (in 9 from 11 samples). 
For one of patient we have registered a couple hun-
dred-fold of an increase in the level of expression of 
AhR by qPCR. We have observed the increased AhR 
expression in tumor cells, however the level of expres-
sion was not connected with the stage of the disease. 
The results of a comparative analysis of the level 
of AhR mRNA in groups of patients suffering from 
different types of cancer were published. The data 
shows that in the tumor tissue of patients with cancer 
of the thyroid gland, pancreas, stomach or colon, the 
mRNA content in the tumor tissue is higher compared 
to non-tumor tissue. However, as noted by Safe et al. 
(2013), AhR mRNA levels were not predictive for pa-
tient survival [14].
Figure. 1. mRNA expression in patient tissues.
P1-11 - patients with colorectal cancer. From the left 
to the right, patients are represented by the increased 
stage of disease according to the classification of TNM 
staging system. For each patient mRNA level in normal 
tissue was taken as 1. mRNA expression level is shown 
in the tumor tissue relative to normal tissue. Height of 
column above 1 indicates overexpression, below — of 
its supression. (A) Relative level of AhR mRNA. (B) 
OCT4B1 mRNA. (C) CYP1A1 mRNA. (D) ABCG2 
mRNA. (E) MDR2 mRNA.
We have compared the levels of excess expression of 
AhR levels in tumor tissue compared to normal tissue 
with expression levels of OCT4B1, a potential marker 
of colon cancer stem cells (figure 1B). We have found 
that in the samples expressing OCT4B1 at an elevated 
level compared to the adjacent normal tissue, the level 
of expression of AhR was also increased. We assume 
that there is a link between the expression level of AhR 
and the enrichment of the tumor population with stem-
like cells potential.
3.2 Expression of CYP1A1 and ABC Family 
Members in Human Colon Cancer
The biotransformation of potentially toxic chemicals 
occurs in two distinct phases, Phase I and Phase II, and 
involves several enzyme systems, the most important 
being the P450 cytochromes. We have compared the 
levels of expression of CYP1A1 in tumor samples and 
adjacent tissues and registered a 2-5-fold increase in 8 
samples out of 12 (figure 1C). To eliminate toxins, the 
body has developed several transporter systems, such 
as the P-glycoprotein, which prevents the absorption 
of chemicals through the gastrointestinal tract by fa-
cilitating their efflux from the enterocytes into the in-
testinal lumen [15]. We were unable to find any increase 
of ABCG2 (figure 1D) expression on the level of tran-
DOI: https://doi.org/10.30564/jor.v1i1.410
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scription, while expression of MDR2 (figure 1E) was 
increased in half of the tumors compared to the levels 
of expression in normal adjacent tissue. No dependen-
cies of the expression levels of the efflux transporters 
of the tumor malignancy stage were found. 
3.3 Calibration Curve for Reporter Cell Line 
To calibrate the reporter cell line we have used FICZ 
as a potent high affinity ligand of the aryl hydrocar-
bon receptor (AhR). A descriptive statistics analysis of 
HEK293T-AhR-luc calibration curve was performed 
using Excel (Microsoft). In this range of concentrations 
calibration curve can be described by the following 
equation y=12.99*x0.19, where y (RLU's) is the lucifer-
ase activity at ligand, (FICZ) is the concentration d (nM) 
(figure 2A). The coefficient of determination R=0.19 
so the model can be considered quite good [16]. A cali-
bration curve allows to determine the concentration of 
PAH in the tissues of the given patients, converts the 
Relative Light Units (RLU’s) to the concentration of 
PAH (nM). We consider the change in level of lucifer-
ase expression in response to the binding of the PAHs 
mixture in the sample to be equivalent to the effect 
of the FICZ. Luciferase activity was correlated to the 
number of viable cells determined by the MTT method.
Figure 2. Measurement of AhR ligands (PAHs) concen-
tration.
Note: (A) Calibration curve for reporter cell line HEK293T-AhR-
luc. P2-10 - patients with colorectal cancer. Nav (average norm) – 
average for the blood of 6 healthy people. (B) Concentration of PAHs 
in blood of patients in RLUs. (C) Concentration of PAHs in blood of 
patients in nM. (D) Concentration of PAHs in a surgical sample of 
cancerous and normal tissue in RLUs. (E) Concentration of PAHs in 
a surgical sample of cancerous and normal tissue in nM. n=3, p<0.05.
3.4 The Concentration of XRE Ligands in the 
Blood of Patients with Colon Cancer
It is known that the defeat of the human body by 
xenobiotics most often and most effectively occurs 
through food chains (up to 96% of the PAH enters the 
human body with food). To answer the question whether 
the presence of colon cancer correlates with the content 
of AhR ligands in the blood serum, we have compared 
the effect of the blood serum of sick and healthy 
people on the level of luciferase expression when cells 
were added to the culture medium of НЕК293Т-AhR-
luc cells. The increase in luciferase expression level 
(RLU’s) reflects the amount of PAHs in the blood of 
patients with CRC. By using the calibration curve we 
have determined the concentration of PAHs in nM. As 
it can be seen from the figure (figure 2B and 2C), for 
6 out of 7 patients, the number of PAHs is higher than 
in the blood of healthy people. We believe that there 
is a correlation between the disease and the level of 
AhR ligands in the blood. It is impossible to determine 
whether a tumor produces endogenous ligands or this 
increase is due to the influx of PAHs from the outside. 
On the basis of the small group of samples, we cannot 
reach a final conclusion about the difference in the 
content of PAH in the blood, however, we assume that 
their level in patients with colorectal cancer is higher 
than that in healthy people. 
3.5 The Concentration of XRE Ligands in the 
Tumor and Normal Tissue of Patients with Co-
lon Cancer
The next question was to compare how the tumor trans-
formation affects the level of ligands in the colon. For 
this, the effect of lysates of tumor tissue and adjacent 
normal mucosa on the level of luciferase expression 
was compared by adding the lysates into the culture 
medium of HEK293T-AhR-luc cells (figure 2D and 
E). It is clear, that the amount of AhR ligands is gets 
lower with increasing malignancy. However significant 
discrepancy between the level of luciferase activity in 
tumor tissue and the normal mucosa of the same patient 
was not registered in 4 out of 6 cases, whereas another 
two patients demonstrated a different character of de-
pendency. We cannot prove the effect of tumor trans-
formation on accumulation of PAHs in tumor tissues. 
Comparison of the levels of ligands in the normal mu-
DOI: https://doi.org/10.30564/jor.v1i1.410
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cosa of patients with CRC has shown high heterogene-
ity (up to 3 times). We are unable to explain the nature 
and causes of this heterogeneity due to small cohort of 
patients.
4. Discussion
Huge progress has been made in the study of AhR 
signaling and the identification of new endogenous 
ligands, including the high-affinity ligand FICZ and 
kinurenin, both of which are tryptophan metabolites [11]. 
However, extensive studies of human AhR are required, 
since the functions of the receptor differ both in dif-
ferent species and in cells of different tissues, and also 
depending on the cellular environment [17]. Ligands of 
AhR not only have different affinities, but also a differ-
ent nature - endogenous and exogenous, and can both 
activate and inhibit the receptor. The proposed reporter 
allows us to determine only the total concentration of 
the ligands of the AhR, there is no possibility to sep-
arate endogenous and exogenous ligands. That is, the 
activity of luciferase expression will reflect the level of 
activation of the AhR signaling pathway in response to 
the entire spectrum of ligands and allows us to observe 
the dynamics of the effect of therapy. The quantitative 
determination of the PAH by the method of mass spec-
troscopy in one sample reaches $ 1,000 and requires 
complex and complicated sample preparation. In this 
sense, the use of the reporter line repeatedly simplifies 
and reduces the cost of analysis, making it possible to 
make it accessible and widely used in both bio-medical 
and environmental studies. Cultivation of reporter cell 
line does not require expensive multicomponent media, 
the analysis is simple to do in many replications, and 
when cultivated, the cells are sufficiently resistant to 
the addition of the test samples to the culture medium. 
In order to check the activation of xenobiotic-metabo-
lizing enzymes as a response to ligand binding to XRE, 
we have determined the expression level of AhR and its 
CYP1A surrogate target in reporter cell line. Our stud-
ies show an mRNA increase for CYP1A after FICZ (0.8 
nM) treatment, while levels of AhR expression were 
similar (data not shown). However, as indicated above, 
a small number of samples does not allow making sta-
tistically reliable conclusions about differences in gene 
expression levels for patients with colorectal cancer 
compared with healthy ones. Therefore, the reporter 
strain can be used to test the content of PAH in various 
materials - water, milk, extracts of meat, fish, juices of 
vegetables and fruits, as well as in biological fluids - 
saliva, blood, urine.
We observe a significant increase of PAH level in the 
serum of patients with CRC independent of stage. We 
believe that we were the first to reveal such a difference 
in the levels of AhR ligands using a simple luciferase 
analysis. A similar pattern of differences was observed 
in the analysis of tissue lysates of tumors and adjacent 
mucosa - in 5 of 6 patients we have noted an increase 
of the PAH from 2-6 times. Proposed system does not 
allow to determine the origin of ligands (accumulation 
of endogenous or the deposition of exogenous).
Recognition of the potential for therapeutic use of 
AhR ligands required considerable experimental data 
and a long time to be confirmed due to well-known 
genotoxicity [14]. In recent reviews there is increasing 
evidence that the AhR and its ligands can be used as 
targets in the development of new drugs for antitumoral 
therapy [11, 14, 18].
The development of drugs that targeted AhR must 
take into account the selectivity property of modula-
tors, manifested in the fact that the receptor ligand will 
serve as AhR agonist or antagonist depending on the 
tissue context [14, 19].
Thus, since it is known that AhR agonists enhance 
the growth of colon and stomach cancer cells, there 
is an assumption about the possible therapeutic 
role of selective modulators exhibiting antagonistic 
activity in this cellular context. In contrast, in most 
pancreatic tumors РАН inhibit cancer cell proliferation 
and anchorage-independent growth [20], suggesting 
that selective agonists will be effective for treating 
pancreatic cancer.
НЕК293Т-AhR-luc test system will allow to study 
the relationship between the concentration of PAHs and 
the degree of tumor malignancy (stage, tumor size, the 
presence of metastases) and serves for development 
of  new selective modulators of  AhR for cancer 
chemotherapy.
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